UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Understanding what stocks are favored by new investors can guide your choices. Explore current buying trends to make informed decisions.
27,622 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
As Cricut reports its 2025 earnings, investors weigh growth engines, profitability, and strategic bets. This guide br...
Grocery Outlet GO's Q4 2025 earnings transcript sheds light on margin discipline, expansion plans, and the path to 20...
AI disruption fears loom over software stocks. This article explains why Unity Software is likely to endure and even ...
Regulatory clarity is on the horizon for digital assets as the Clarity Act advances. This guide breaks down three key...
A practical guide to interpreting Champions Oncology earnings. We break down the numbers, trends, and what to watch n...
As AI reshapes enterprise tech, investors wonder if CrowdStrike can translate vigilance into lasting outsized returns...
Rivian’s April milestone could reshape its growth path. This article breaks down why April could huge for Rivian, wha...
Iren is pursuing a bold AI infrastructure push with a $4.4 billion target. This article breaks down what that means f...
The Trade Desk is testing a strategy that could redefine cross-platform audience reach. Audience Unlimited Could Trad...
Markets reassess the Warsh era as fresh inflation figures arrive. Inflation data confirms kevin and pushes investors ...
SpaceX pursues space-based AI data centers ahead of a 2026 IPO, stirring talk of a market shakeout as investors weigh...